1. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
- Author
-
Schleiermacher, G, Mosseri, V, London, WB, Maris, JM, Brodeur, GM, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, Speleman, F, Noguera, R, Tonini, GP, Fischer, M, Ambros, I, Monclair, T, Matthay, KK, Ambros, P, Cohn, SL, Pearson, ADJ, Schleiermacher, G, Mosseri, V, London, WB, Maris, JM, Brodeur, GM, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, Speleman, F, Noguera, R, Tonini, GP, Fischer, M, Ambros, I, Monclair, T, Matthay, KK, Ambros, P, Cohn, SL, and Pearson, ADJ
- Abstract
BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/ or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients > 18 months and in stage 4 disease (P
- Published
- 2012